Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC
NCT07134556 · MedSIR · PHASE2 · withdrawn · last registry update 2026-05-01 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The interim analysis of the STAR-221 study showed that the domvanalimab combination did not improve overall survival compared to standard of care. No new relevant safety concerns were identified.” | Open Targets' class: negative | Registry record, MedSIR |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDCD1 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-22Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab + Carboplatin (NCT03036488)
- 2026-07-27Results posted on the registry: Medical College of Wisconsin, Cemiplimab + Paclitaxel (NCT04243616)
- 2025-05-29Results posted on the registry: Yuan Yuan, Pembrolizumab + Olaparib (NCT03025035)
- 2025-05-13Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab tirumotecan + Pembrolizumab (NCT06966700)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision